CSL Ltd (CSL.AX)

CSL.AX on Australia Stock Exchange

82.57AUD
28 Nov 2014
Price Change (% chg)

$-0.45 (-0.54%)
Prev Close
$83.02
Open
$83.00
Day's High
$83.21
Day's Low
$82.42
Volume
3,014,071
Avg. Vol
1,104,118
52-wk High
$83.33
52-wk Low
$63.77

CSL.AX

Chart for CSL.AX

About

CSL Limited is an Australia-based company. The Company is engaged in the research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. The Company operates in three segments: CSL Behring, Intellectual Property Licensing and Other Human Health. CSL Behring manufactures markets and... (more)

Overall

Beta: 0.41
Market Cap (Mil.): $39,437.04
Shares Outstanding (Mil.): 475.03
Dividend: 0.65
Yield (%): 1.49

Financials

  CSL.AX Industry Sector
P/E (TTM): 26.36 37.69 38.55
EPS (TTM): 3.15 -- --
ROI: 24.90 17.92 17.25
ROE: 42.30 18.73 18.17
Search Stocks

Australia's CSL buys Novartis flu vaccine unit for $275 million

SYDNEY/ZURICH - Australia's CSL Ltd , the world's largest blood products company, said on Monday it had agreed to buy Novartis AG's global influenza vaccine business for $275 million, part of the Swiss drugmaker's drive to focus on its best assets.

27 Oct 2014

UPDATE 1-Australia's CSL buys Novartis flu vaccine unit for $275 mln

SYDNEY/ZURICH, Oct 27 - Australia's CSL Ltd , the world's largest blood products company, said on Monday it had agreed to buy Novartis AG's global influenza vaccine business for $275 million, part of the Swiss drugmaker's drive to focus on its best assets.

27 Oct 2014

BRIEF-CSL Ltd to acquire Novartis influenza vaccine business

Oct 27 - CSL Ltd : * CSL to acquire novartis influenza vaccine business * Agreed to acquire novartis' global influenza vaccine business for US$275 million * Business will be combined with csl's subsidiary, biocsl * Final settlement of the transaction is expected to occur in the second half of calendar year 2015 * Acquisition synergies are estimated to reach US$75 million per annum by fiscal year 2020 * Integration costs are estimated at $us100 million, accruing predominantly in

26 Oct 2014

Australia's CSL buys Novartis influenza vaccine unit for $275 million

SYDNEY - Australia's CSL Ltd , the world's largest blood products company, said on Monday it had agreed to buy Novartis AG's global influenza vaccine business for $275 million.

26 Oct 2014

Australia's CSL buys Novartis influenza vaccine unit for $275 mln

SYDNEY, Oct 27 - Australia's CSL Ltd, the world's largest blood products company, said on Monday it had agreed to buy Novartis AG's global influenza vaccine business for $275 million.

26 Oct 2014

Australia's CSL, Ansell join global medical response to Ebola

SYDNEY - Australian biotech firm CSL Ltd, the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill & Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak.

17 Oct 2014

UPDATE 1-Australia's CSL, Ansell join global medical response to Ebola

SYDNEY, Oct 17 - Australian biotech firm CSL Ltd , the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill & Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak.

17 Oct 2014

Australia's CSL, Ansell join global medical response to Ebola

SYDNEY, Oct 17 - Australian biotech firm CSL Ltd , the world's second-biggest blood products maker, said on Friday it's working on a plasma product to treat Ebola following a request from the Bill & Melinda Gates Foundation, part of a growing commercial response to the deadly outbreak.

17 Oct 2014

Australia shares seen slipping, but greenback rise may buoy exporters

MELBOURNE, Sept 10 - Australian shares are set to open lower on Wednesday after Wall Street fell, but a rise in the U.S. dollar may shore up the market's biggest exporters, like the miners, blood products maker CSL and packaging group Amcor. * Local share price index futures fell 0.3 percent to 5,586.0, which was a 21.9-point discount to the underlying S&P/ASX 200 index close. The benchmark rose 0.5 percent on Tuesday. * New Zealand's benchmark NZX 50 index slipped 0.2

09 Sep 2014

Australia shares slip on Ukraine worry, Wall Street but CSL earnings buoy

* 67 shares higher, 117 shares lower, 16 shares unchanged. (Adds analysis, quotes, stocks on the move)

13 Aug 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks